|
MechanismAKR1B1 inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase II, multicenter, multinational, randomized, double-blinded, placebo-controlled dose-finding study to evaluate the efficacy and safety of carbabenzpyride in the treatment of uncomplicated influenza A.Prospective, multicenter, multinational, randomized, double-blinded, placebo-controlled dose-finding study in parallel groups (Phase II)
100 Clinical Results associated with Farmak International Holding GmbH
0 Patents (Medical) associated with Farmak International Holding GmbH
100 Deals associated with Farmak International Holding GmbH
100 Translational Medicine associated with Farmak International Holding GmbH